| NCT06957483 | Pilot Study of a Sedentary Behaviour Intervention for Individuals With a Spinal Cord Injury | Brunel University | | - Age ≥ 18 yrs
- Level T1-S5
AIS - All
| Active | 20 | NA | Psychosocial/other | General health | - Adverse Events (AEs)
- Blood Pressure and Heart Rate Regulation
- Feasibility
- Generalized Anxiety Disorder (GAD-7)
- Patient Health Questionnaire-9 (PHQ-9)
- Short Form 36 (SF-36)
| 8 weeks | 12 May 2025 | 04 May 2025 | 1 | |
| NCT07237035 | Reclaiming Independence: Daily Activities and Rehabilitation Goals in Spinal Cord Injury | Medipol University | | - Age 18 - 60 yrs
- Level C1-S5
AIS - All
| Ended | 56 | | | Arm/hand function | | 0 days | 03 November 2025 | 19 November 2025 | 1 | |
| NCT07227727 | Endothelial Dysfunction After SCI | Craig Hospital | | - Age ≥ 18 yrs
- Level T2-S5
AIS A, B- ≥ 12 months
| Recruiting | 40 | | | General health | | 0 days | 31 July 2025 | 13 November 2025 | 1 | |
| NCT07227740 | Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury | Craig Hospital | | - Age 18 - 89 yrs
- Level T3-S5
AIS A, B- ≥ 6 months
| Recruiting | 48 | | | General health | | 0 days | 15 July 2025 | 13 November 2025 | 1 | |
| NCT06808035 | Understanding Perinatal Spinal Cord Injury | University of Louisville | | - Age 3 - 8 yrs
- Level C1-C8
AIS - All
- NOT currently use a baclofen pump
- be diagnosed with a perinatal (injured in utero or at birth) spinal cord injury
| By invitation | 6 | NA | Technology | General health | - Box and Block Test (BBT)
- Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP)
- Neurogenic Bowel Dysfunction Score (NBD or NBDS)
- Neuromuscular Recovery Scale
- Pendulum Test (Wartenberg)
- Sensory evoked potentials (including mixed and dermatomal, mSSEPs, dSSEPs, contact heat/laser evoked potentials- CHEPS/LEPs)
- Surface Electromyography (sEMG)
| 2 months | 09 January 2024 | 05 February 2025 | 1 | |
| NCT06974968 | Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | | - Age 18 - 65 yrs
- Level C4-L2
AIS A, B, C- 14 days - 60 days
| Recruiting soon | 60 | PHASE2 | Biological/cell based | General health | - Adverse Events (AEs)
- American Spinal Injury Association Impairment Scale (AIS)
- International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
- Spinal Cord Independence Measure (SCIM)
| 1 year | 25 May 2028 | 16 May 2025 | 1 | |
